60 results on '"Bismar, Tarek A."'
Search Results
2. Supplementary Figure legends from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
3. Supplementary Figure 3 from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
4. Supplementary Figure 4 from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
5. Supplementary Figure 3 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
6. Supplementary Figure 4 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
7. Supplementary Table S1 from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
8. CCR Translation for This Article from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
9. Supplementary Table 1 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
10. Supplementary Table 1 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
11. Supplementary Figure Legends 1-5 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
12. Supplementary Figure 2 from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
13. Supplementary Figure 7 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
14. Supplementary Figure 3 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
15. Supplementary Figure 1 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
16. CCR Translation for This Article from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
17. Supplementary Figure 3 from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
18. Data from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
19. Supplementary Figure 1 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
20. Supplementary Figure 5 from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
21. Supplementary Figure 5 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
22. Supplementary Figure 4 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
23. Supplementary Figure 2 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
24. Supplementary Figure 5 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
25. Supplementary Table S2 from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
26. Supplementary Figure 6 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
27. Supplementary Material from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
28. Supplementary Figure 2 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
29. Supplementary Figure 2 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
30. Supplementary Figure 1 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
31. Supplementary Figure 5 from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
32. Supplementary Figure 1 from Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
33. Supplementary Figure Legends 1-5 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
34. Supplementary Figure 4 from TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair
35. Supplementary Figure 5 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
36. Supplementary Figure 3 from PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
37. Supplementary Figure 1 from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
38. Data from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
39. Supplementary Figure 4 from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
40. Supplementary Figure 3 from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
41. Supplementary Figure 3 from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
42. Supplementary Figure 2 from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
43. Supplementary Figure 4 from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
44. Supplementary Figure 2 from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
45. Supplementary Methods, Figure Legends 1-4 from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
46. Supplementary Figure 1 from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
47. Supplementary Methods, Figure Legends 1-4 from A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
48. Abstract 2012: Recurrent rearrangements of NAALADL2 in prostate, breast, cervical, head and neck and lung squamous cell carcinoma
49. Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer
50. Abstract 4971: Splicing factor kinase regulates metastatic dissemination of human prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.